Presentations focus on COVID-19; HIV cure, pathogenesis, treatment and long-term complications; tuberculosis; hepatitis C; and contraception.
Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the world’s largest HIV research network whose focus has expanded to include evaluating outpatient treatment for COVID-19, will present four oral presentations, two themed discussions, and 23 poster sessions at the Conference on Retroviruses and Opportunistic Infections (CROI 2022), which will be held February 19-22, 2023 in Seattle, Washington. CROI is the premier global HIV research conference and ACTG’s robust presence at the meeting demonstrates its continued leadership in HIV and related fields.
“The studies the ACTG is presenting at CROI this year represent important advances across the research agenda for the group, including HIV, COVID-19, hepatitis C, and TB, and they demonstrate that after more than 35 years, the ACTG continues to be a leader in research,” said ACTG Chair Judith Currier, M.D., MSc, of the University of California, Los Angeles. “We are especially excited to share insights in eight presentations about COVID-19, which we believe make important contributions to our understanding of SARS-CoV-2. We’re also proud to present findings on a number of long-term complications related to HIV and to highlight important findings in TB, including drug-resistant TB, and hepatitis C. Much of the work presented this year is led by a talented group of emerging investigators engaged with the ACTG. The ACTG remains committed to advancing research in these fields to ultimately improve the lives of people affected by these conditions.”
ACTG presentations are listed below by topic.
Read more here: https://www.eurekalert.org/news-releases/979658